Imunon (IMNN) Enterprise Value (2010 - 2026)
Imunon's (IMNN) quarterly Enterprise Value came in at -$4.8 million in Q1 2026, down 66.94% YoY from -$14.5 million in Q1 2025, and up 45.4% on a QoQ basis from -$8.8 million in Q4 2025.
Imunon (IMNN) Enterprise Value (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Enterprise Value data on file, last reported at -$4.8 million in Q1 2026.
- Quarterly Enterprise Value fell 66.94% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.8 million (down 66.94% YoY) and the FY2025 annual result came in at -$8.8 million, down 49.52% from the prior year.
- Enterprise Value climbed to -$4.8 million in Q1 2026, from -$8.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.9 million in Q1 2025 to a low of -$42.1 million in Q2 2022.
- A 5-year average of -$17.0 million and a median of -$11.2 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 77.9% — and 2026, when it sank 66.94%.
- Tracing IMNN's Enterprise Value over 5 years: stood at -$32.7 million in 2022, then surged by 52.07% to -$15.7 million in 2023, then soared by 62.58% to -$5.9 million in 2024, then sank by 49.52% to -$8.8 million in 2025, then jumped by 45.4% to -$4.8 million in 2026.
- The last three Enterprise Value figures came in at -$4.8 million (Q1 2026), -$8.8 million (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 2.12 Bn |
| 10 | Imunon | 8.58 Mn | 8.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | -8.78 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Jun 30, 2025 | -4.73 Mn |
| Mar 31, 2025 | -2.87 Mn |
| Dec 31, 2024 | -5.87 Mn |
| Jun 30, 2024 | -5.31 Mn |
| Mar 31, 2024 | -9.81 Mn |
| Dec 31, 2023 | -15.70 Mn |
| Sep 30, 2023 | -19.36 Mn |
| Jun 30, 2023 | -24.01 Mn |
| Mar 31, 2023 | -12.65 Mn |
| Dec 31, 2022 | -32.75 Mn |
| Sep 30, 2022 | -37.35 Mn |
| Jun 30, 2022 | -42.11 Mn |
| Mar 31, 2022 | -41.31 Mn |
| Dec 31, 2021 | -49.40 Mn |
| Sep 30, 2021 | -54.51 Mn |
| Jun 30, 2021 | -58.36 Mn |
| Mar 31, 2021 | -52.76 Mn |